A study of Fabry disease in 36 women (mean [SD] age, 47.0 [17.9] years) found that 25 (69 %) had LVH at baseline; after 4 years of agalsidase alfa ERT, there was significant reduction in LVMI in 22/25 (88 %) patients who had LVH at baseline, with 7/25 (28 %) no longer classified as having LVH [25]. This evidence concerns the gene GLA and Fabry disease.